StockNews.com Initiates Coverage on Chimerix (NASDAQ:CMRX)

StockNews.com assumed coverage on shares of Chimerix (NASDAQ:CMRX) in a research note published on Wednesday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently issued reports on CMRX. Wedbush reissued a “neutral” rating and set a $8.55 target price (up previously from $7.00) on shares of Chimerix in a report on Wednesday, March 5th. HC Wainwright restated a “neutral” rating and issued a $8.55 target price (down previously from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $8.50 price target (down from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Price Performance

Shares of NASDAQ CMRX opened at $8.54 on Wednesday. The stock has a market capitalization of $801.09 million, a PE ratio of -9.09 and a beta of -0.17. Chimerix has a one year low of $0.75 and a one year high of $8.55. The business’s fifty day moving average price is $7.39 and its 200-day moving average price is $3.97.

Chimerix (NASDAQ:CMRX) last posted its earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.01. The business had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.31 million. As a group, equities analysts expect that Chimerix will post -0.99 EPS for the current fiscal year.

Insider Activity at Chimerix

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the sale, the chief executive officer now directly owns 609,603 shares in the company, valued at $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last quarter, insiders sold 20,760 shares of company stock valued at $91,175. Company insiders own 13.10% of the company’s stock.

Institutional Trading of Chimerix

Several institutional investors and hedge funds have recently made changes to their positions in CMRX. Bender Robert & Associates bought a new position in Chimerix in the fourth quarter valued at $37,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Chimerix in the 4th quarter worth about $59,000. Jane Street Group LLC bought a new position in shares of Chimerix during the 4th quarter valued at about $62,000. Diadema Partners LP purchased a new position in shares of Chimerix during the 4th quarter valued at about $101,000. Finally, Squarepoint Ops LLC bought a new stake in Chimerix in the 4th quarter worth approximately $130,000. Hedge funds and other institutional investors own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.